Get the Stockscreener App
61.16
0.02%
-0.01
After Hours:
61.16
Vaxcyte Inc stock is traded at $61.16, with a volume of 986.69K.
It is down -0.02% in the last 24 hours and up +11.83% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$61.17
Open:
$59.73
24h Volume:
986.69K
Relative Volume:
0.70
Market Cap:
$9.10B
Revenue:
-
Net Income/Loss:
$-946.53M
P/E Ratio:
-8.7793
EPS:
-6.9664
Net Cash Flow:
$-814.94M
1W Performance:
+2.21%
1M Performance:
+11.83%
6M Performance:
+1.71%
1Y Performance:
+90.23%
1-Day Range:
$59.65
$61.78
1-Week Range:
$58.51
$62.90
52-Week Range:
$30.81
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
61.16 | 9.13B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone - AOL.com
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte (PCVX) Rallies 3.7% to $60.22 as Vaccine Pipeline Momentum BuildsBPI Bear Confirmed - vinanet.vn
PCVX Q2 2026 Earnings: Narrower-than-Expected Loss Yields 3.7% Share GainEPS Estimate Trend - vinanet.vn
Vaxcyte (PCVX) Climbs 3.14% to $59.90, Approaching Key Resistance at $62.90Breakaway Gap - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left - Kavout | AI
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
Odyssean, LLC's Vaxcyte Inc(PCVX) Holding History - GuruFocus
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research - MarketBeat
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline - DirectorsTalk Interviews
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients - Stock Titan
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
FMR LLC (PCVX) discloses 20.8M-share beneficial stake in Vaxcyte common stock - Stock Titan
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
PCVX SWOT Analysis: Key Financial Insights Revealed in 10-Q Fili - GuruFocus
Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares - marketbeat.com
Vaxcyte (PCVX) Advances Phase 3 Trials Amid Mixed Market Signals - GuruFocus
Vaxcyte, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock - MarketBeat
Vaxcyte Q2 net loss widens on higher expenses - TradingView
Vaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary - TradingView
PCVX: Phase 3 VAX-31 adult trials fully enrolled; OPUS-1 topline data expected Q4 2026 - TradingView
Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance - Stock Titan
Vaxcyte reports $2.5B cash; Q2 net loss $284.3M, R&D up to $267.9M - TradingView
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. SEC Filing (Aug 5, 2026) - Stock Titan
BRIEF-Vaxcyte Q2 Operating Expenses USD 302.777 Million - TradingView
Press Release: Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
PCVX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
PCVX (PCVX) holder plans August 3 sale after option exercise - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking The 101.55% Potential Upside - DirectorsTalk Interviews
PCVX (PCVX): insider Andrew Guggenhime plans 10,000-share stock sale - Stock Titan
Current ratio of Vaxcyte, Inc. – XETR:5VA - TradingView
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Liquidity Mapping Around (PCVX) Price Events - Stock Traders Daily
59,061 Shares in Vaxcyte, Inc. $PCVX Purchased by Stempoint Capital LP - MarketBeat
Vaxcyte Inc (PCVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vaxcyte (PCVX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wassil Jim | CHIEF OPERATING OFFICER |
Sep 01 '26 |
Sale |
61.07 |
3,477 |
212,352 |
155,041 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):